Discovery of high-affinity peptide binders to BLyS by phage display

Journal of Molecular Recognition : JMR
Tony J FlemingDaniel J Sexton

Abstract

B lymphocyte stimulator (BLyS) is a tumor necrosis factor (TNF) family member and a key regulator of B cell responses. We employed a phage display-based approach to identify peptides that bind BLyS with high selectivity and affinity. Sequence analysis of first-generation BLyS-binding peptides revealed two dominant peptide motifs, including one containing a conserved DxLT sequence. Selected linear peptides with this motif were found to bind BLyS with K(D) values of 1-3 microM. In order to improve the binding affinity for BLyS, consensus residues flanking the DxLT sequence were seeded into a second-generation, BLyS affinity maturation library (BAML). BAML phage were subjected to stringent binding competition conditions to select for isolates expressing high-affinity peptide ligands for BLyS. Post-selection analysis of BAML peptide sequences resulted in the identification of a core decapeptide motif (WYDPLTKLWL). Peptides containing this core motif exhibited K(D) values as low as 26 nM, approximately 100-fold lower than that of first-generation peptides. A fluorescence anisotropy assay was developed to monitor the protein-protein interaction between BLyS labeled with a ruthenium chelate, and TACI-Fc, a soluble form of a BLyS recep...Continue Reading

References

Jun 19, 1998·Current Opinion in Structural Biology·D A Marvin
Jul 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·H B Shu, H Johnson
Nov 21, 2000·The Journal of Experimental Medicine·M BattenF Mackay
Dec 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J ZhangT Zhou
May 24, 2001·Immunity·G U von BülowR J Bram
Apr 6, 2002·Biotechnology Progress·Aaron K SatoRobert C Ladner
Apr 10, 2002·Analytical and Bioanalytical Chemistry·Axel DürkopOtto S Wolfbeis
Apr 19, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bernie ScallonCarrie Wagner
Jun 5, 2002·Biochimica Et Biophysica Acta·Jung Sook KangJoseph R Lakowicz
Nov 13, 2002·Annual Review of Immunology·Fabienne MackayJeffrey Browning
Dec 26, 2002·Journal of Molecular Recognition : JMR·A V VeselovskyP Janssen
Jan 4, 2003·Chembiochem : a European Journal of Chemical Biology·Sachdev S SidhuKurt Deshayes
Apr 11, 2003·Arthritis and Rheumatism·Robert H Carter

❮ Previous
Next ❯

Citations

Feb 24, 2010·Parasitology Research·Aijiang GuoXuenong Luo
Jun 15, 2006·Analytical Chemistry·Kristin A FletcherIsiah M Warner
Nov 12, 2009·Protein Engineering, Design & Selection : PEDS·Sophia A Kenrick, Patrick S Daugherty
Mar 1, 2006·International Journal of Peptide Research and Therapeutics·Lauren R H Krumpe, Toshiyuki Mori
Apr 1, 2007·Expert Opinion on Drug Discovery·Lauren Rh Krumpe, Toshiyuki Mori
Jul 28, 2010·Biotechnology Advances·Jyoti PandeAshok K Grover
Jul 11, 2006·Immunology·Stéphanie HaiatJean-Pierre Kolb
Oct 20, 2006·Current Opinion in Biotechnology·Aaron K SatoClive R Wood
Feb 15, 2007·Journal of Chromatography. a·Fu-Feng LiuYan Sun
Feb 18, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Thomas LindnerWalter Mier
May 23, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jonathan M GershoniYael Weiss
Aug 2, 2006·Molecular BioSystems·A M Levin, G A Weiss
Jun 6, 2020·Expert Opinion on Investigational Drugs·Rossella TalottaMagdalena Janina Laska
Aug 10, 2005·Protein Engineering, Design & Selection : PEDS·A ShrivastavaA D Nunn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.